-
-
-
Source Antibodies Cross reactivity Blocking receptor binding Target Complex crystal (PDB ID) Binding affinity (Kd nmol/L) Neutralizing effect (IC50 μg/mL or nmol/L) Current status Refs. Convalescent SARS patients 47D11 Yes No RBD NA 9.6b 0.57† μg/mL Under research Wang C et al. (2020) S309 Yes No RBD (Site B) 6WPS 0.001b 0.079† μg/mL Under research Pinto et al. (2020) CR3022 Yes No RBD (Site C) 6W41 < 0.1b No Under research Yuan et al. (2020b) Immunized llama VHH-72-Fc Yes Yes RBD NA 38.6a 0.2* μg/mL Under research Wrapp et al. (2020a) Convalescent COVID-19 patients P2C-1F11 No Yes RBD (Site A) NA 2.12a 0.03† μg/mL Under research Ju et al. (2020) P2B-2F6 No Yes RBD (Site A) 7BWJ 5.14a 0.41† μg/mL Under research CA1 No Yes RBD (Site A) NA 4.68 ± 1.64a 4.981† μg/mL Under research Shi et al. (2020) CB6 (JS016) No Yes RBD (Site A) 7C01 2.49 ± 1.65a 0.835† μg/mL Phase-I B38 No Yes RBD (Site A) 7BZ5 70.1a 0.177† μg/mL Under research Wu Y et al. (2020) H4 No Yes RBD (Site A) NA 4.48a 0.896† μg/mL Under research 414-1 No Yes RBD (Site A) NA 0.31c 1.75† nmol/L Under research Wan et al. (2020) 505-3 No Yes RBD (Site A) NA 0.08c 3† nmol/L Under research BD-23 NA Yes RBD (Site A) 7BYR 4.3a 8.5† μg/mL Under research Cao et al. (2020) BD-368-2 NA Yes RBD (Site A) NA 0.82a 0.015† μg/mL Under research CC6.29 No Yes RBD (Site A) NA 1.20a 0.002* μg/mL Under research Rogers et al. (2020) CC6.30 No Yes RBD (Site A) NA 1.71a 0.001* μg/mL Under research CC12.1 No Yes RBD (Site A) 6XC2 5.92a 0.022* μg/mL Under research Yuan et al. (2020a) CC12.3 No Yes RBD (Site A) 6XC4 54.3a 0.026* μg/mL Under research 4A8 NA No NTD (Site D) 7C2L 1.00b 0.39† μg/mL Under research Chi et al. (2020) 2–4 NA Yes RBD (Site A) 6XEY NA 0.057† μg/mL Under research Liu LH et al. (2020) 2–15 NA Yes RBD NA NA 0.0007† μg/mL Under research 4–8 NA No NTD NA NA 0.009† μg/mL Under research 2–43 NA Yes RBD NA NA 0.003† μg/mL Under research COV2-2196 No Yes RBD NA NA 0.015† μg/mL Under research Zost et al. (2020) COV2-2130 No Yes RBD NA NA 0.107† μg/mL Under research S2M11 No Yes RBD (Site A) 7K43 66a 1.66† μg/mL Under research Poh et al. (2020) S2E12 No Yes RBD (Site A) 7K4N 1.6a 5.29† μg/mL Under research LY-CoV555 No Yes RBD NA NA NA Phase III (pause) Jones et al. (2020) REGN10933 No Yes RBD 6XDG 0.0140a 0.043† nmol/L Phase III Baum et al. (2020) VelocImmune mice REGN10987 No Yes RBD 6XDG 0.0298a 0.041† nmol/L Phase III Phage library n3088 NA No RBD (Site C) NA 12.6b 3.3* μg/mL Under research Wu YL et al. (2020) n3130 NA No RBD (Site C) NA 32.5b 3.7* μg/mL Under research n3086 NA No RBD NA 88.97b 26.6* μg/mL Under research n3113 NA No RBD NA 57.01b 18.9* μg/mL Under research H014 Yes Yes RBD (Site C) NA 0.33b 1* nmol/L Under research Lv et al. (2020) †The data were derived from authentic virus neutralization experiments
* The data were derived from the pseudovirus neutralization experiments
aThe data obtained using surface plasmon resonance (SPR)
bThe data obtained using biolayer interferometry (BLI)
cThe data obtained using enzyme-linked immunosorbent assay (ELISA)
*The data were derived from the pseudovirus neutralization experiment (other data derived from authentic virus neutralization experiments)Table 1. Characteristics of representative antibodies to SARS-CoV-2.
Figure 2 个
Table 1 个